Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3b Multicenter, Open-Label Single Arm Study of Roxadustat: Either as Conversion From an Erythropoiesis Stimulating Agent (ESA), or as Initial Anemia Treatment in Hemodialysis (HD) Patients

NCT04484857 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT04484857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04484857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3b Multicenter, Open-Label Single Arm Study of Roxadustat: Either as Conversion From an Erythropoiesis Stimulating Agent (ESA), or as Initial Anemia Treatment in Hemodialysis (HD) Patients
Lead sponsor
Kyntra Bio
Phase
Phase 3
Overall status
Completed
Start date
July 22, 2020
Completion date
September 17, 2021
Enrollment
283 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

anemia associated with end stage renal disease